XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.2

COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2023
Commitments And Contingencies [Line Items]
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones			$ 765.5
Purchase commitment			253.0
Purchase commitments expected to be paid in 2023			194.6
Early Stage Development Program | Third Party
Commitments And Contingencies [Line Items]
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones	$ 381.5	$ 210.0
Shareholder vs BioMarin Pharmaceutical Inc
Commitments And Contingencies [Line Items]
Loss contingency			$ 39.0

X

- Definition

Commitments and contingencies.

+ References

No definition available.

+ Details

Name:	bmrn_CommitmentsAndContingenciesLineItems
Namespace Prefix:	bmrn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones.

+ References

No definition available.

+ Details

Name:	bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
Namespace Prefix:	bmrn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482425/460-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482425/460-10-50-2

+ Details

Name:	us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.

+ References

No definition available.

+ Details

Name:	us-gaap_PurchaseObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.

+ References

No definition available.

+ Details

Name:	us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=bmrn_ThirdPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=bmrn_ShareholderVsBioMarinPharmaceuticalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: